Advertisement

Topics

Correction: Announcement no. 3/2019 – Coloplast responds to FDA’s decision to remove Surgical Transvaginal Mesh as Treatment Option for Pelvic Organ Prolapse

05:09 EDT 17 Apr 2019 | Biotech 365

Announcement no. 3/201917 April 2019   Coloplast responds to FDA’s decision to remove Surgical Transvaginal Mesh as Treatment Option for Pelvic Organ Prolapse Coloplast was informed yesterday by the FDA that the PMA for Restorelle DirectFix Anterior is not approved and … Continue reading

Original Article: Correction: Announcement no. 3/2019 – Coloplast responds to FDA’s decision to remove Surgical Transvaginal Mesh as Treatment Option for Pelvic Organ Prolapse

NEXT ARTICLE

More From BioPortfolio on "Correction: Announcement no. 3/2019 – Coloplast responds to FDA’s decision to remove Surgical Transvaginal Mesh as Treatment Option for Pelvic Organ Prolapse"

Advertisement
Quick Search
Advertisement
Advertisement

 

Relevant Topics

Surgical treatments
Surgery is a technology consisting of a physical intervention on tissues. All forms of surgery are considered invasive procedures; so-called "noninvasive surgery" usually refers to an excision that does not penetrate the structure being exci...

Drug Approvals
In order to become availible to pateints, drugs need to undergo a number of phases of clinical trials to test their efficacy and safty and to then be authorised by the drug approval organistion in each respective country. This is the FDA in the USA and N...